blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1199071

EP1199071 - Use of an estrogen agonist/antagonist for improving vascular health [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  30.03.2007
Database last updated on 12.07.2024
Most recent event   Tooltip09.11.2007Change - lapse in a contracting state
State(s) deleted from list of lapses: IT		published on 12.12.2007  [2007/50]
Applicant(s)For all designated states
Pfizer Products Inc.
Eastern Point Road
Groton, CT 06340 / US
[N/P]
Former [2006/21]For all designated states
Pfizer Products Inc.
Eastern Point Road Groton
Connecticut 06340 / US
Former [2002/17]For all designated states
Pfizer Products Inc.
Eastern Point Road
Groton, Connecticut 06340 / US
Inventor(s)01 / Day, Wesley W Pfizer Global Research & Development
Eastern Point Road
Groton, Connecticut 06340 / US
02 / Lee, Andrew G Pfizer Global Research & Development
Eastern Point Road
Groton, Connecticut 06340 / US
03 / Thompson, D., Pfizer Global Research & Development
Eastern Point Road
Groton, Connecticut 06340 / US
 [2002/17]
Representative(s)Rutt, Jason Edward, et al
Pfizer
ATTENTION: ADDRESS INACTIVE - USE ASS-NR - CDR / FR
[N/P]
Former [2005/13]Rutt, Jason Edward, et al
Pfizer Limited European Patents Department, Ramsgate Road
Sandwich, Kent CT13 9NJ / GB
Former [2002/17]Sewell, Richard Charles, et al
UK Patent Department, Pfizer Limited, Ramsgate Road
Sandwich, Kent CT13 9NJ / GB
Application number, filing date01308806.716.10.2001
[2002/17]
Priority number, dateUS20000241532P17.10.2000         Original published format: US 241532 P
[2002/17]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP1199071
Date:24.04.2002
Language:EN
[2002/17]
Type: A3 Search report 
No.:EP1199071
Date:29.10.2003
[2003/44]
Type: B1 Patent specification 
No.:EP1199071
Date:24.05.2006
Language:EN
[2006/21]
Search report(s)(Supplementary) European search report - dispatched on:EP12.09.2003
ClassificationIPC:A61K31/40, A61P9/10, A61P9/00, A61P13/12
[2005/49]
CPC:
A61K31/4709 (EP,US); A61K31/517 (EP,KR,US); A61K31/00 (EP,US);
A61K31/40 (EP,US); A61K31/404 (EP,US); A61K31/4439 (EP,US);
A61K31/47 (EP,US); A61K31/506 (EP,US); A61P13/12 (EP);
A61P15/00 (EP); A61P25/04 (EP); A61P25/08 (EP);
A61P3/06 (EP); A61P35/00 (EP); A61P43/00 (EP);
A61P5/32 (EP); A61P7/00 (EP); A61P9/00 (EP);
A61P9/10 (EP) (-)
Former IPC [2003/43]A61K31/00, A61K31/40, A61P9/10, A61P9/00, A61P13/12, A61P3/06, A61K31/46, A61K31/445
Former IPC [2002/17]A61K31/00, A61K31/40, A61P9/10, A61P9/00, A61P13/12, A61P3/06
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   TR [2002/17]
TitleGerman:Verwendung von Östrogen Agonist/Antagonist zur Verbesserung der vaskulären Gesundheit[2002/17]
English:Use of an estrogen agonist/antagonist for improving vascular health[2002/17]
French:Utilisation d'un agoniste/antagoniste estrogénique pour améliorer la santé vasculaire[2002/17]
Examination procedure02.11.2001Examination requested  [2002/17]
24.02.2004Despatch of a communication from the examining division (Time limit: M04)
22.06.2004Reply to a communication from the examining division
19.07.2004Despatch of a communication from the examining division (Time limit: M02)
03.09.2004Reply to a communication from the examining division
18.10.2004Despatch of a communication from the examining division (Time limit: M01)
11.11.2004Reply to a communication from the examining division
09.12.2004Despatch of a communication from the examining division (Time limit: M02)
03.02.2005Reply to a communication from the examining division
23.02.2005Despatch of a communication from the examining division (Time limit: M02)
28.04.2005Reply to a communication from the examining division
09.05.2005Despatch of a communication from the examining division (Time limit: M04)
08.09.2005Reply to a communication from the examining division
03.11.2005Communication of intention to grant the patent
13.03.2006Fee for grant paid
13.03.2006Fee for publishing/printing paid
Opposition(s)27.02.2007No opposition filed within time limit [2007/18]
Fees paidRenewal fee
24.10.2003Renewal fee patent year 03
25.10.2004Renewal fee patent year 04
31.10.2005Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipMC31.10.2006
[2007/50]
Former [2007/37]IT24.05.2006
MC31.10.2006
Former [2007/36]IT24.05.2006
Documents cited:Search[Y]US5407955  (BRYANT HENRY U [US], et al) [Y] 1,6 * page 1, line 9 - line 14 *;
 [X]US5567714  (BRUNS JR ROBERT F [US], et al) [X] 1,6 * column 9, line 54 - line 61 * * column 10, line 1 * * claim 4 *;
 [X]US5595722  (GRAINGER DAVID J [GB], et al) [X] 1,6 * column 2, line 11 - line 24 * * column 7, line 50 - line 52 * * column 2, line 33 - line 35 * * column 2, line 50 - line 55 *;
 [X]US5747509  (KAUSER KATALIN [US], et al) [X] 1,6 * column 1, line 15 - line 18 * * column 4, line 59 - line 61 * * column 7, line 18 - line 30 * * claim 1 *;
 [Y]EP0842659  (PFIZER [US]) [Y] 1,6 * claim 3 * * page 2, line 5 - line 9 * * page 2, line 32 * * page 4, line 46 - line 47 * * page 5, line 28 - line 31 *;
 [X]US5968918  (KANDA IWAO [US]) [X] 1,6 * claim 4 * * column 2, line 9 - line 20 *;
 [Y]US6034102  (AIELLO ROBERT J [US]) [Y] 1-7 * claims 1,2,8 * * column 6, line 15 - line 17 * * column 8, line 8 - line 14 *;
 [Y]  - DANIEL VOET, JUDITH G. VOET, Biochemie, 1992, VCH VERLAGSGESELLSCHAFT, XP002252452 [Y] 1-7 * page 303 - page 303 *
Examination   - ST CLAIR R.W., "Estrogens and atherosclerosis: Phytoestrogens and selective estrogen receptor modulators", CURRENT OPINION IN LIPIDOLOGY, LONDON, GB, (1998), vol. 9, no. 5, pages 457 - 463, XP002126541
    - LEBUFFE G. ET AL, "ENDOTHELIAL DERIVED VASORELAXATION IS IMPAIRED IN HUMAN APO A-I TRANSGENIC RABBITS", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, USA, (199712), vol. 241, pages 205 - 211, XP002918532

DOI:   http://dx.doi.org/10.1006/bbrc.1997.7790
    - GIBBONS G.H.; DZAU V.J., "MOLECULAR THERAPIES FOR VASCULAR DISEASES", SCIENCE AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, (199605), vol. 272, pages 689 - 693, XP000857348

DOI:   http://dx.doi.org/10.1126/science.272.5262.689
    - HARRISON D.G. ET AL, "ALTERATIONS OF VASCULAR REACTIVITY IN ATHEROSCLEROSIS", CIRCULATION RESEARCH, GRUNE AND STRATTON, (1987), vol. 61, no. 5, pages II-74 - II-80, XP009043924
    - CRUETZIG A.; CASPARY L., "PROSTANOIDS IN THERAPY OF PERIPHERAL ARTERIAL OCCLUSIVE DISEASE", THERAPIE, PARIS, FR, (199105), vol. 46, no. 3, pages 241 - 245, XP009038902
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.